David Tai

4.4k citations
77 papers · 1.6k · 2 hit papers · h-index 20

Impact in

  • Hepatology top 2%
    • Hepatocellular Carcinoma Treatment and Prognosis
  • Oncology top 5%
    • Cancer Immunotherapy and Biomarkers
    • Pancreatic and Hepatic Oncology Research
    • CAR-T cell therapy research

Papers in

    • Cancer Immunotherapy and Biomarkers 12
    • Pancreatic and Hepatic Oncology Research 8
    • Colorectal Cancer Treatments and Studies 5
    • Hepatocellular Carcinoma Treatment and Prognosis 26

David Tai

73 papers receiving 1.6k citations

David Tai's Hit Papers

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. 2024 · 83 citations
830+1+3Years since publication50100150200250

Peers

David Tai
Comparison fields: 5 of 78
  • Hepatology 449
  • Oncology 613
  • Immunology 233
  • Gastroenterology 51
  • Cancer Research 121
Replace Ірина Давиденко with:
Ірина Давиденко United States
Antonia Digklia Switzerland
Mehmet Akce United States
Cécile Charpy France
Chung Yip Chan Singapore
Skye C. Mayo United States
Mashaal Dhir United States
Olivier Dubreuil France
Daisuke Ban Japan
Natsuko Okita Japan
David Tai relative to Ірина Давиденко United States Ірина Давиденко's profile →
Citations per field
00.5×10×15×19×
Ірина Давиденко · 1×
Citations per year

Countries citing papers authored by David Tai

Since Specialization
Citations

This map shows the geographic impact of David Tai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Tai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Tai more than expected).

Fields of papers citing papers by David Tai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Tai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Tai. The network helps show where David Tai may publish in the future.

Co-authors

The 25 scholars most cited alongside David Tai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Tai Line = papers co-authored together David Tai links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 77 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Hit paper breakdown →
2021271
2 2015120
3 2020105
4
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
Hit paper breakdown →
202483
5 201179
6 201574
7 202169
8 202153
9 201246
10 201045
11 201639
12 201537
13 202435
14 202335
15 201730
16 201929
17 201529
18 201829
19 202022
20 201922

About David Tai

David Tai is a scholar working on Oncology, Hepatology, Pulmonary and Respiratory Medicine, Molecular Biology and Surgery, having authored 77 papers that have together received 1.6k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (26 papers), Cancer Immunotherapy and Biomarkers (12 papers), Pancreatic and Hepatic Oncology Research (8 papers), Fibroblast Growth Factor Research (7 papers), Cancer Genomics and Diagnostics (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers), Colorectal Cancer Treatments and Studies (5 papers) and Eosinophilic Disorders and Syndromes (5 papers). The work is most often cited by research in Hepatology (449 citations), Oncology (613 citations), Immunology (233 citations), Gastroenterology (51 citations) and Cancer Research (121 citations). David Tai has collaborated with scholars based in Singapore, South Korea and United States. Frequent co-authors include Su Pin Choo, Valerie Chew, Joycelyn Jie Xin Lee, Connie Yip, Armando Santoro, Yun Hua Lee, Brian K. P. Goh, Pierce K. H. Chow, John J. Arcaroli and Keith Wells. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Liver Cancer, Surgery and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact